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1. Introduction 
Nonalcoholic fatty liver disease (NAFLD), which includes nonalcoholic steatosis and 
nonalcoholic steato- hepatitis (NASH), describes the clinicopathologic spectrum of alcohol-
like liver disease in the nonalcoholic [Ludwig et al 1980]. 
Although it may be observed as an iatrogenic complication (due to drugs or anti-obesity 
surgery) or secondary to various other conditions (toxins, lipodystrophic syndromes, 
hypobetalipoproteinemia), NAFLD most commonly occurs as a primary (idiopathic) 
disease. 
The clinical importance of primary NAFLD appears to rest on three main observations: 
• It commonly occurs in the general population worldwide and among patients 
presenting with unexplained mild to moderate raised aminotransferase levels . 
• It is not a sign or symptom of disease but it is a pathological condition that has the 
potential to progress to advanced hepatic and extrahepatic disease ,and to interact with 
other etiologies of liver disease . 
• It may recur following orthotopic liver transplantation and poses a heavy burden of 
complications in the setting of major extrahepatic and liver-related surgery . 
2. Reported risk factors 
The conventional risk factors for the development of primary NAFLD include type II 
diabetes, insulin resistance, hyperlipidemia and obesity (Mezey,1998). NAFLD typically 
affects 50% of diabetics and 76% of obese patients (Bellantini et al 2000;Gupte et al.2004), 
and is the most common of all liver diseases. However, the prevalence of NASH is 
substantially less, affecting 18.5% of obese patients. 
Other traditional risk factors include hyperuricemia, central obesity defined as waist 
circumference greater than 100 cm in males and greater than 88 cm in females, and 
hypertension. 
Secondary causes of NAFLD include nutrition-related complications, such as total 
parenteral nutrition, rapid weight loss, and intestinal jejunoileal bypass surgery. Common 
causes of Steatosis is mention in Table.1.  
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Nonalcoholic fatty liver disease 
Alcohol 
Drugs—estrogens, coumadin, tamoxifen, valproic acid, methotrexate, isoniazid, 
corticosteroids, vitamin A, troglitazone, l-asparaginase, amiodarone, perhexiline, calcium 
channel blockers, nucleoside analogues 
Hepatitis C (genotype 3) 
Nutritional factors—rapid weight loss, total parenteral nutrition 
Surgical considerations—gastrointestinal surgery for obesity, extensive small-bowel 
resection 
Metabolic disorders—cystic fibrosis, abetalipoproteinemia, others 
Syndromes associated with obesity, insulin resistance—lipodystrophies, hypopituitarism, 
Prader-Willi syndrome 
Table 1. Conditions Associated With Macrovesicular Steatosis 
Certain drugs are associated with NAFLD.  Metabolic syndromes and pregnancy-related 
fatty liver diseases are also some of the secondary causes of NAFLD. Patients with normal 
body mass index (BMI) may develop NAFLD even in the absence of traditional risk factors. 
It is thought that the primary abnormality may be occult insulin resistance or central 
adiposity (Lee et al.1998). 
The natural history of NAFLD still remains poorly defined. Mortality among NAFLD 
patients approaches 13%, which is greater than age- and sex-matched controls (6). Because 
these patients often have features of the metabolic syndrome, they are at high risk for 
cardiac-related death. Hence, both ischemic heart disease and malignancy are the leading 
causes of death in patients with NAFLD. However, liver disease is the third most common 
cause of mortality in this population, accounting for 13% of all deaths. This is significantly 
different than patients without NAFLD, in whom liver-related causes of mortality account 
for less than 1% of all deaths (Adams et al 2005). Clinical predictors of more advanced 
disease include people with diabetes, hypertriglyceridemia (Caldwell et al.1999) and those 
older than 40 years of age. Table.2. outlines the diagnostic criteria for NAFLD. 
 
Parameter Value 
Impaired glucose tolerance Fasting blood glucose l vel ≥110 mg/dL(5.6mmol/L) 
High blood pressure ≥130/85 mm Hg 
Elevated triglyceride levels >250 mg/dL(1.7mmol/L) 
Low high-density lipoprotein
level 
<40 mg/dL (1.00mmol/L)for men; <50 mg/dL(1.3mmol/L)
for women 
Abdominal obe ity 
Waist: >102 cm (40 inches  for men; >88 cm (35 inches) for 
women 
 
Table 2. Diagnostic Criteria for the Metabolic Syndrome: Presence of Two or More of the 
Following Parameters 
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3. Diagnosis 
Most patients with NAFLD are asymptomatic or suffer from nonspecific symptoms and 
signs such as fatigue, malaise or right upper quadrant pain. In most cases, the diagnosis is 
suspected in the context of the appropriate risk factor profile and incidental elevation of 
transaminases. Levels of aspartate aminotransferase and alanine aminotransferase are 
modestly elevated, although the ratio of aspartate aminotransferase to alanine 
aminotransferase is less than one, distinguishing NAFLD patients from those with alcohol-
induced liver disease (Bacon et al.1994).  
The International Federation of Clinical Chemistry and Laboratory Medicine established in 
2002 a reference system for the measurement of enzyme activity of clinically important 
enzymes, including ALT, to be measured at 37 °C 23. Levels of 10-45 U/l are considered as 
normal, although reference values may still vary among laboratories.  
The degree of elevation of transaminases does not reflect the underlying severity of the 
disease. The diagnosis of NAFLD can be suspected on the basis of radiological imaging such 
as ultrasound or magnetic resonance imaging. 
However, the sensitivity of these modalities is low and often there is a significant degree of 
interobserver variability. A minimum of 30% of hepatocytes needs to be infiltrated by 
steatosis for the imaging techniques to detect fatty liver (Saadeh et al.2002). 
Currently, the only method of distinguishing simple steatosis from NASH is the liver 
biopsy. Brunt et al (1999) proposed a grading and staging system for NASH. Grade 1 reveals 
mild steatosis, predominantly macrovesicular with minimal ballooning of hepatocytes and 
minimal inflammation. Grade 2 shows moderate steatosis, usually mixed macrovesicular 
and microvesicular with ballooning present in zone 3 hepatocytes, and some lobular 
inflammation. Grade 3 shows all the features of grade 2 plus the additional requirement of 
portalinflammation. Staging requires the presence of Masson trichrome stain. Stage 1 reveals 
zone 3 perivenular, perisinusoidal fibrosis, either focal or extensive. Stage 2 requires the 
features of stage 1, plus focal or extensive portal fibrosis. Stage 3, shows bridging fibrosis 
and stage 4 reveals cirrhosis with or without perisinusoidal fibrosis. 
4. Pathogenesis 
The progression from simple steatosis to steatohepatitis, fibrosis and cirrhosis is thought to 
be a two-hit hypothesis. 
4.1 First hit 
The first hit results in fat accumulation within the liver parenchyma. This occurs in 
abnormalities during uptake, synthesis and secretion of lipids resulting primarily from 
insulin resistance, which is quite common in patients with NAFLD (Marchesni et al.2001). 
Insulin resistance is often a primary abnormality in patients with NAFLD. There is often a 
genetic predisposition to insulin resistance, even in the absence of frank diabetes. Twenty 
per cent of the nondiabetic population may exhibit insulin resistance. Patients that exhibit 
more pronounced levels of insulin resistance exhibit a greater degree of steatosis (Angelico 
et al.2005). Central adiposity may contribute to the flow of excess free fatty acids (FFAs) to 
the liver by providing a direct route through the portal vein (Scheen and Luyckx. 2002). 
Patients with NAFLD often have risk factors such as type II diabetes, hyperlipidemia, 
hypertension and obesity, which are part of the insulin resistance syndrome. 
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Hyperinsulinemia promotes lipolysis in the adipocyte, resulting in increased FFAs delivered 
to the liver. In the hepatocyte, FFAs stimulate synthesis of more FFAs and inhibit oxidation 
of FFAs (Harrison et al.2002). The following figure 1. explains how expanded visceral mass 
leads to increased release of free fatty acids(FFA) from adipose tissue due to insulin 
resistance (IR)..  
 
 
Fig. 1. Expansion of Visceral Fat Mass  May Lead to Dyslipidemia and Insulin Resistance 
The increased flux of free fatty acids into the liver results in the formation and secretion of 
very low density lipoprotein (VLDL)rich in Triglycerides. Inhibition or reduced activity of 
Lipoprotein lipase LPL) results in the distribution and formation of TG rich High density 
lipoprotein and Low density lipoprotein (LDL). Hepatic lipase acts on them to form small 
dense HDL and LDL ( Dyslipidemia). 
Insulin sensitivity is also influenced by peptide mediators, otherwise known as 
adipocytokines, such as tumour necrosis factoralpha (TNF-α), leptin and adiponectin and 
although the mechanisms by which this occurs remain largely unknown, theories are 
suggested. TNF-α influences steatosis by stimulating the release of FFAs from adipocytes 
into the liver.(Fig.2.) 
TNF-α may directly induce apoptosis of hepatocytes promoting activation of hepatic stellate 
cells, stimulating fibrosis (Festi et al.2004). Leptin( Leptin resistance which is considered to 
be one of the possible third hit hypothesis) potentially may stimulate platelet-derived 
growth factor, ultimately leading to hepatic stellate cell proliferation resulting in fibrosis 
(Kejima et al.2005). Adiponectin may have a protective role against fatty liver. Recently it 
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was shown that adiponectin levels were significantly reduced in patients with NAFLD 
compared with controls resulting in an inverse relationship between insulin resistance and 
adiponectin levels (Saargin et al.2005). This observation may result in a future therapeutic 
role in the pharmacological management of NAFLD. 
 
 
Fig. 2. Visceral Fat As a Major Site of Hormone Production, Inflammatory Markers and Its 
Possible Relationship including Type 2 Diabetes 
4.2 Second hit 
The second hit is hepatocellular injury that results from oxidative stress, lipid peroxidation 
and direct cellular toxicity from FFAs (hitture and Farrell 2001). Multiple mechanisms 
regarding hepatocyte injury have been proposed: 
1. Increased expression of cytochrome P450 isoform CYP2E1 has been shown to occur in 
patients with NASH. CYP2E1 is a pro-oxidant, resulting in increased production of 
reactive oxygen species, capable of peroxidizing cell membranes. 
2. Increased insulin leads to peripheral lipolysis resulting in excess fatty acids which 
catalyzes lipid peroxisomes. Peroxisomes are involved in the oxidation process of fatty 
acids. Oxidation, along with binding and export of fatty acids, is the primary method of 
protecting the liver from subsequent damage. 
3. The peroxisome proliferators activated receptor-alpha (PPAR-α) is responsible for 
regulating the esterification and export of fatty acids in very low density lipoprotein, in 
the binding of fatty acids and in mitochondrial and peroxisomal oxidation. Reduced 
expression of PPAR-α may have an important role in the pathogenesis of NASH (Yeon 
et al.2004). 
4. Mitochondrial abnormalities have been described in patients with NASH, but not in 
those with simple steatosis. These mitochondrial abnormalities lead to increased 
mitochondrial fatty acids beta-oxidation, eventually resulting in free radical formation 
hepatocyte injury and steatohepatitis. Patients who are insulin resistant but do not have 
mitochondrial abnormalities may develop fatty liver; however, generally they do not 
progress to steatohepatitis (Sanyal et al.2001). 
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5. Methods of managing the disease 
Currently, management is aimed at lifestyle modification, primarily targeting weight loss 
achieved through dietary modification and exercise. Additionally, treatment of all other 
aspects of the metabolic syndrome must be instituted. Weight loss and exercise both 
improve insulin resistance (Cox et al.2004), which theoretically should improve steatosis. No 
randomized controlled study has been run to evaluate whether histological regression 
occurs in patients with steatohepatitis or fibrosis after weight loss, although case reports and 
open-label studies suggest improvement. Weight loss should not exceed more than 1 kg per 
week, because rapid weight loss can exacerbate steatosis. Similarly very low calorie diets 
that give less than 500 kcal/day and jejunoileal bypass surgery should be avoided as a 
method of weight loss, due to the risk of worsening fibrosis. The recommended target for 
weight loss is 10% of a person’s body weight over a six-month period 
(Angulo,2002).Multiple popular diets exist as methods of weight loss). Some diets are 
founded on years of medical experience, while others have deviated substantially from 
mainstream medical advice The Weight Watchers program is one of the traditional models, 
restricting portion sizes and total calories consumed. Other popular diets include 
carbohydrate restriction without fat restriction (Atkins diet), macronutrient and glycemic 
load modification (Zone diet) and fat restriction (Ornish diet). The following figure gives an 
idea about the distribution of fat in various compartments and the markers that indicate 
these compartments respectively  
 
 
*As a Marker of Fat Measurement in various compartments BMI-Body Mass Index, Waist 
Circumference, Serum Alanine Aminotransferase (ALT) 
Fig. 3. Distribution of Fat 
In obese patients with BMI greater than 35 kg/m2, no significant differences were found 
regarding amount of weight lost at the end of one year (Dansinger et al.2005). Reduction of 
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cardiovascular risk factors correlated with amount of weight loss. Weight loss of 3 kg to 6 kg 
over one year was achieved regardless of type of diet followed. Currently, no data exist 
regarding various types of diets in patients with NASH. 
6. Medications that could induce weight loss 
Medications to reduce weight are not routinely used in the treatment of NAFLD, and have 
not been studied in randomized clinical trials. One case series suggested that orlistat in 
patients with NASH was safe, and showed significant histological improvement in both 
degree of steatohepatitis and fibrosis after six to 12 months of therapy (Harrison et al.2003). 
Orlistat is a reversible inhibitor of gastric and pancreatic lipase, and is one of two agents that 
have been approved for the management of obesity. This medication forms a covalent bond 
with the active serine residue of gastric and pancreatic lipase in the stomach and small 
bowel, blocking the digestion and absorption of dietary triglycerides. Orlistat in 
combination with a controlled energy diet, rather than diet alone, significantly increased 
weight loss in obese adults after one year of therapy (Davidson et al.1999). 
The second approved drug in the management of obesity is sibutramine. Sibutramine was 
evaluated in one nonrandomized study in patients with NASH (Sabuncu et al.2003). 
Sibutramine in combination with a low calorie diet-induced weight loss improved insulin 
resistance and transaminases, as shown by ultrasonographic regression in fatty liver, 
compared with diet alone. It is a noradrenaline-serotonin reuptake inhibitor and produces 
weight loss by a dual mechanism: reduction of food intake and increase in energy 
expenditure. Average weight loss is in the range of 5% to 8% from baseline. Recently, 
rimonabant, a selective cannabinoid-1 receptor blocker, has been shown to improve 
cardiovascular risk factor profile and reduce body weight(Despres et al.2005). Over 1000 
overweight patients with BMIs between 27 kg/m2 and 40 kg/m2 participated in this study 
examining the effects of rimonabant and metabolic risk factors. Mean weight loss was 6.6 kg 
over 12 months at a dose of 20 mg.  
 
 
Fig. 4. WAIST HIP RATIO (WHR) AS A MEASURE OF Visceral Adiposity 
Additionally, waist circumference was reduced, plasma high density lipoprotein levels 
increased, and plasma adiponectin levels were significantly higher in patients receiving 
rimonabant compared with placebo. This medication, and other weight reducing agents, 
may represent future therapeutic options for the pharmacological treatment of obese 
patients with NASH. 
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Certainly, diet should be combined with exercise to initiate and maintain weight loss. 
Exercise will enhance calorie deficit necessary for weight loss. A minimum of 30 min of 
moderate sustained activity five days per week is necessary to gain health benefits from 
exercise (28). Any fitness regimen should include a balance of aerobic exercise,  strength and 
flexibility training 
7. Pharmacotherapy for NAFLD 
Currently, there are no approved pharmacological options for the treatment of NAFLD. 
Only three randomized controlled trials have been conducted to evaluate the efficacy of 
medical treatment in NAFLD (Table 3). The agents studied include antioxidants with 
vitamins E and C in combination, ursodeoxycholic acid and metformin. Although there was 
improvement in liver enzymes and steatosis in the trial evaluating metformin, there was no 
improvement in steatohepatitis or fibrosis at follow-up. The other two trials did not suggest 
any improvement in liver enzymes, steatosis, steatohepatitis or fibrosis. The remaining trials 
performed to date have been observational in design, had small sample size, and have had a 
short follow-up period. The thiazolidinediones are a class of insulin-sensitizing agents used 
to treat type II diabetes. Troglitazone was evaluated in an open-label trial involving 10 
patients for duration of four to six months (Caldwell et al.2001). These patients had 
improvement in transaminases and liver histology. However, this medication was 
subsequently withdrawn from the market due to serious hepatic toxicity. Both rosiglitazone 
(Neuschwander-Tetri et al.2003) and pioglitazone (Promrat et al.2003) have been studied in 
open-label design, and have shown improvement in transaminases, steatosis and fibrosis. 
Recently VSL#3 was shown to lower markers of lipid peroxidation in patients with NASH 
(Loguercico et al.2005). However, larger randomized studies are needed before routine 
recommendation of these agents in the treatment of NASH.  
 
 
Strategy Treatment 
Weight loss 
Caloric restriction, exercise; sibutramine, orlistat; weight reduction 
surgery 
Insulin-sensitizing 
agents 
Metformin; peroxisome proliferator-activated receptor-gamma 
agonists (thiazolidinedione, rosiglitazone, pioglitazone) 
Lipid-lowering 
drugs 
Fibrates (gemfibrozil), fish oil 
Antioxidants N-acetylcysteine, vitamin E, betaine 
 
Table. 3. Therapeutic Approaches for Nonalcoholic Fatty Liver Disease 
8. Bariatric surgery 
In the early age of bariatric surgery, jejunoileal bypass was the procedure most commonly 
performed. 
A substantial proportion of patients developed advanced liver disease, presumably from 
bacterial overgrowth and endotoxemia in the bypassed intestine, resulting in bacterial 
translocation and liver disease. However, the jejunoileal bypass surgery has seldom been 
performed in recent years due to the multiple complications arising from this procedure. A 
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recent meta-analysis suggested that surgical therapy for weight loss was superior to other 
methods of weight loss in patients with BMI greater than 40 kg/m2 (Maggard et al.2005). 
This weight loss was sustained for a 10-year follow-up. Although there was a trend toward 
improved weight loss in patients with BMI between 35 kg/m2 and 39 kg/m2 in the 
surgically treated group, the data cannot be considered conclusive. Recently, one study 
evaluated laparascopic surgical weight loss via one of three techniques: roux-en-Y gastric 
bypass laparascopic adjustable gastric band and sleeve gastrectomy in patients with 
established NAFLD and metabolic syndrome. 
Mean BMI was 56 kg/m2 (Mattar et al.2005). Patients had liver biopsies at the time of the 
bariatric surgery followed by a repeat biopsy after 15 months. Mean excess weight loss at 
the time of the second biopsy was 59%. There was a marked improvement in live steatosis, 
steatohepatitis and fibrosis. In fact, in some patients, inflammation and fibrosis completely 
resolved. Additionally, there was improvement in the metabolic risk factor profile. 
Hence, as newer methods of bariatric surgery become more popular, there may be a future 
role for this type of surgery in morbidly obese patients with NASH. 
9. Whether liver biopsy is mandatory? 
Often, NAFLD is a diagnosis of exclusion. Patients are given advice regarding lifestyle 
modifications and re-evaluated clinically and biochemically several months later in routine 
follow-up. This may be a reasonable approach for the time being because there are no 
effective medications in the treatment of NAFLD. However, as pharmacotherapy becomes 
an option in the future, this line of thought may need to be revised. The distinction between 
pure fatty change and steatohepatitis can only be made histologically. This distinction is 
important because NAFLD has a benign prognosis, whereas NASH progresses toward 
cirrhosis. Because of the risk of NASH in patients suspected to have fatty liver, it could be 
argued that all patients should be offered a liver biopsy to stage the disease. However, in 
terms of logistics, cost and side effects, this may not be possible. Hence, it is reasonable to 
biopsy patients with risk factors for more advanced disease such as advancing age, obesity, 
hypertension and diabetes mellitus. Additionally, the liver biopsy may occasionally reveal 
unsuspected abnormalities indicating an alternate or additional diagnosis to fatty 
liver(Younossi, 2008). 
10. Conclusions 
Obesity epidemic is a global phenomena carrying with the risk of precipitating insulin 
resistant states including NAFLD which is shown to be on the rise. The primary abnormality 
for NAFLD reported is that of intrinsic insulin resistance. Therefore NAFLD could be one of 
the risk factors for the development of Type II Diabetes (Guido et al.2011). There seems to be 
no approved  pharmacological therapies for the treatment of NASH. The major suggested 
treatment continues to be weight loss therapy through diet and exercise, and aggressive risk 
factor control.  
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triglycerides. However, efforts of the last decade have identified several molecules that are secreted from
adipocytes, such as leptin, which are involved in signaling between tissues and organs. These adipokines are
important in overall regulation of energy metabolism and can regulate body composition as well as glucose
homeostasis. Excess lipid storage in tissues other than adipose can result in development of diabetes and
nonalcoholic fatty liver disease (NAFLD). In this book we review the role of adipocytes in development of
insulin resistance, type 2 diabetes and NAFLD. Because type 2 diabetes has been suggested to be a disease
of inflammation we included several chapters on the mechanism of inflammation modulating organ injury.
Finally, we conclude with a review on exercise and nutrient regulation for the treatment of type 2 diabetes and
its co-morbidities.
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